Carbapenems to treat multidrug and extensively drug-resistant tuberculosis: A systematic review

International Journal of Molecular Sciences

Volumn 17, Issue 3, 2016, Pages

  Sotgiu, Giovanni ^a   D’Ambrosio, Lia ^b,c   Centis, Rosella ^b   Tiberi, Simon ^d   Esposito, Susanna ^e   Dore, Simone ^a   Spanevello, Antonio ^f,g   Migliori, Giovanni Battista ^b  

^a UNIVERSITY OF SASSARI   (Italy)

^b WORLD HEALTH ORGANIZATION   (Switzerland)

^c Public Health Consulting Group SAGL   (Switzerland)

^d ROYAL LONDON HOSPITAL   (United Kingdom)

^e UNIVERSITY OF MILAN   (Italy)

^f IRCCS   (Italy)

^g UNIVERSITY OF INSUBRIA   (Italy)

Author keywords

Carbapenems; Effectiveness; Ertapenem; Imipenem; MDR TB; Meropenem; Safety; Tolerability; XDR TB

Indexed keywords

CARBAPENEM DERIVATIVE; ERTAPENEM; IMIPENEM; MEROPENEM; BETA LACTAM; THIENAMYCIN DERIVATIVE; TUBERCULOSTATIC AGENT;

BACTERIUM CULTURE; DEMOGRAPHY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EXTENSIVELY DRUG RESISTANT TUBERCULOSIS; GEOGRAPHIC DISTRIBUTION; HUMAN; LUNG DISEASE; MULTIDRUG RESISTANT TUBERCULOSIS; REVIEW; SYSTEMATIC REVIEW; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; CLINICAL STUDY; EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS; TUBERCULOSIS, MULTIDRUG-RESISTANT;

ANTITUBERCULAR AGENTS; BETA-LACTAMS; CARBAPENEMS; CLINICAL STUDIES AS TOPIC; EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS; HUMANS; IMIPENEM; THIENAMYCINS; TREATMENT OUTCOME; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 84962616828     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms17030373     Document Type: Review

References (54)

1. World Health Organization. Global Tuberculosis Report 2015; Document WHO/HTM/TB/2015. 22; World Health Organization: Geneva, Switzerland, 2015.
2. Skrahina, A.; Hurevich, H.; Zalutskaya, A.; Sahalchyk, E.; Astrauko, A.; van Gemert, W.; Hoffner, S.; Rusovich, V.; Zignol, M. Alarming levels of drug-resistant tuberculosis in Belarus: Results of a survey in Minsk. Eur. Respir. J. 2012, 39, 1425-1431. [CrossRef] [PubMed].
3. Migliori, G. B.; Sotgiu, G.; Gandhi, N. R.; Falzon, D.; DeRiemer, K.; Centis, R.; Hollm-Delgado, M. G.; Palmero, D.; Pérez-Guzmán, C.; Vargas, M. H.; et al. The Collaborative Group for Meta-Analysis of Individual Patient Data in MDR-TB. Drug resistance beyond extensively drug resistant tuberculosis: Individual patient data meta-analysis. Eur. Respir. J. 2013, 42, 169-179. [CrossRef] [PubMed].
4. Falzon, D.; Gandhi, N.; Migliori, G. B.; Sotgiu, G.; Cox, H.; Holtz, T. H.; Hollm-Delgado, M. G.; Keshavjee, S.; DeRiemer, K.; Centis, R.; et al. Collaborative Group for Meta-Analysis of Individual Patient Data in MDR-TB. Resistance to fluoroquinolones and second-line injectable drugs: Impact on multidrug-resistant TB outcomes. Eur. Respir. J. 2013, 42, 156-168. [CrossRef] [PubMed].
5. Diel, R.; Rutz, S.; Castell, S.; Schaberg, T. Tuberculosis: Cost of illness in Germany. Eur. Respir. J. 2012, 40, 143-151. [CrossRef] [PubMed].
6. Diel, R.; Vandeputte, J.; de Vries, G.; Stillo, J.; Wanlin, M.; Nienhaus, A. Costs of tuberculosis disease in the European Union: A systematic analysis and cost calculation. Eur. Respir. J. 2014, 43, 554-565. [CrossRef] [PubMed].
7. Falzon, D.; Jaramillo, E.; Schünemann, H. J.; Arentz, M.; Bauer, M.; Bayona, J.; Blanc, L.; Caminero, J. A.; Daley, C. L.; Duncombe, C.; et al. WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update. Eur. Respir. J. 2011, 38, 516-528. [CrossRef] [PubMed].
8. Migliori, G. B.; de Iaco, G.; Besozzi, G.; Centis, R.; Cirillo, D. M. First tuberculosis cases in Italy resistant to all tested drugs. Eurosurveillance 2007, 12, E070517. 1. [PubMed].
9. Caminero, J. A.; Scardigli, A. Classification of antituberculosis drugs: A new proposal based on the most recent evidence. Eur. Respir. J. 2015, 46, 887-893. [CrossRef] [PubMed].
10. Sotgiu, G.; Pontali, E.; Migliori, G. B. Linezolid to treat MDR-/XDR-Tuberculosis: Available evidence and future scenarios. Eur. Respir. J. 2015, 45, 25-29. [CrossRef] [PubMed].
11. Emanuele, P.; Giovanni, S.; D'Ambrosio, L.; Rosella, C.; Giovanni, B. M. Bedaquiline and MDR-TB: A systematic and critical analysis of the evidence. Eur. Respir. J. 2016. in press.
12. Esposito, S.; D'Ambrosio, L.; Tadolini, M.; Schaaf, H. S.; Luna, J. C.; Marais, B.; Centis, R.; Dara, M.; Matteelli, A.; Blasi, F.; et al. ERS/WHO Tuberculosis consilium assistance with extensively drug-resistant tuberculosis management in a child: Case study of compassionate delamanid use. Eur. Respir. J. 2014, 44, 811-815. [CrossRef] [PubMed].
13. Skripconoka, V.; Danilovits, M.; Pehme, L.; Tomson, T.; Skenders, G.; Kummik, T.; Cirule, A.; Leimane, V.; Kurve, A.; Levina, K.; et al. Delamanid improves outcomes and reduces mortality in multidrug-resistant tuberculosis. Eur. Respir. J. 2013, 41, 1393-1400. [CrossRef] [PubMed].
14. Gler, M. T.; Skripconoka, V.; Sanchez-Garavito, E.; Xiao, H.; Cabrera-Rivero, J. L.; Vargas-Vasquez, D. E.; Gao, M.; Awad, M.; Park, S. K.; Shim, T. S.; et al. Delamanid for multidrug-resistant pulmonary tuberculosis. N. Engl. J. Med. 2012, 366, 2151-2160. [CrossRef] [PubMed].
15. Pym, A. S.; Diacon, A. H.; Tang, S. J.; Conradie, F.; Danilovits, M.; Chuchottaworn, C.; Vasilyeva, I.; Andries, K.; Bakare, N.; de Marez, T.; et al. Bedaquiline in the treatment of multi-and extensively drug-resistant tuberculosis. Eur. Respir. J. 2015. [CrossRef].
16. Diacon, A. H.; Pym, A.; Grobusch, M.; Patientia, R.; Rustomjee, R.; Page-Shipp, L.; Pistorius, C.; Krause, R.; Bogoshi, M.; Churchyard, G.; et al. The diarylquinoline TMC207 for multidrug-resistant tuberculosis. N. Engl. J. Med. 2009, 360, 2397-2405. [CrossRef] [PubMed].
17. Diacon, A. H.; Pym, A.; Grobusch, M. P.; de los Rios, J. M.; Gotuzzo, E.; Vasilyeva, I.; Leimane, V.; Andries, K.; Bakare, N.; de Marez, T.; et al. Multidrug-resistant tuberculosis and culture conversion with bedaquiline. N. Engl. J. Med. 2014, 371, 723-732. [CrossRef] [PubMed].
18. Guglielmetti, L.; Le Dû, D.; Jachym, M.; Henry, B.; Martin, D.; Caumes, E.; Veziris, N.; Métivier, N.; Robert, J.; Andrejak, C.; et al. Compassionate use of bedaquiline for the treatment of multidrug-resistant and extensively drug-resistant tuberculosis: Interim analysis of a French cohort. Clin. Infect. Dis. 2015, 60, 188-194. [CrossRef] [PubMed].
19. Ndjeka, N.; Conradie, F.; Schnippel, K.; Hughes, J.; Bantubani, N.; Ferreira, H.; Maartens, G.; Mametja, D.; Meintjes, G.; Padanilam, X.; et al. Treatment of drug-resistant tuberculosis with bedaquiline in a high HIV prevalence setting: An interim cohort analysis. Int. J. Tuberc. Lung Dis. 2015, 19, 979-985. [CrossRef] [PubMed].
20. Tiberi, S.; de Lorenzo, S.; Centis, R.; Viggiani, P.; D'Ambrosio, L.; Migliori, G. B. Bedaquiline in MDR/XDR-TB cases: First experience on compassionate use. Eur. Respir. J. 2014, 43, 289-292. [CrossRef] [PubMed].
21. Tiberi, S.; D'Ambrosio, L.; de Lorenzo, S.; Viggiani, P.; Centis, R.; Migliori, G. B. Tuberculosis elimination, patients' lives and rational use of new drugs: Revisited. Eur. Respir. J. 2015. [CrossRef] [PubMed].
22. Migliori, G. B.; Eker, B.; Richardson, M. D.; Sotgiu, G.; Zellweger, J. P.; Skrahina, A.; Ortmann, J.; Girardi, E.; Hoffmann, H.; Besozzi, G.; et al. A retrospective TBNET assessment of linezolid safety, tolerability and efficacy in MDR-TB. Eur. Respir. J. 2009, 34, 387-393. [CrossRef] [PubMed].
23. Villar, M.; Sotgiu, G.; D'Ambrosio, L.; Raymundo, E.; Fernandes, L.; Barbedo, J.; Diogo, N.; Lange, C.; Centis, R.; Migliori, G. B. Linezolid safety, tolerability and efficacy to treat multidrug-and extensively drug-resistant tuberculosis. Eur. Respir. J. 2011, 38, 730-733. [CrossRef] [PubMed].
24. De Lorenzo, S.; Centis, R.; D'Ambrosio, L.; Sotgiu, G.; Migliori, G. B. On linezolid efficacy and tolerability. Eur. Respir. J. 2012, 39, 770-772. [CrossRef] [PubMed].
25. Sotgiu, G.; Centis, R.; D'Ambrosio, L.; Alffenaar, J. W. C.; Anger, H. A.; Caminero, J. A.; Castiglia, P.; de Lorenzo, S.; Ferrara, G.; Koh, W. J.; et al. Efficacy, safety and tolerability of linezolid containing regimens in treating MDR-TB and XDR-TB: Systematic review and meta-analysis. Eur. Respir. J. 2012, 40, 1430-1442. [CrossRef] [PubMed].
26. Sotgiu, G.; Centis, R.; D'Ambrosio, L.; Spanevello, A.; Migliori, G. B. Linezolid to treat extensively drug-resistant TB: Retrospective data are confirmed by experimental evidence. Eur. Respir. J. 2013, 42, 288-290. [CrossRef] [PubMed].
27. Lee, M.; Lee, J.; Carroll, M. W.; Choi, H.; Min, S.; Song, T.; Via, L. E.; Goldfeder, L. C.; Kang, E.; Jin, B.; et al. Linezolid for treatment of chronic extensively drug-resistant tuberculosis. N. Engl. J. Med. 2012, 367, 1508-1518. [CrossRef] [PubMed].
28. Sotgiu, G.; Centis, R.; D'Ambrosio, L.; Castiglia, P.; Migliori, G. B. Low minimal inhibitory concentrations of linezolid against multidrug-resistant tuberculosis strains. Eur. Respir. J. 2015, 45, 287-289. [CrossRef] [PubMed].
29. De Lorenzo, S.; Alffenaar, J. W.; Sotgiu, G.; Centis, R.; D'Ambrosio, L.; Tiberi, S.; Bolhuis, M. S.; van Altena, R.; Viggiani, P.; Piana, A.; et al. Efficacy and safety of meropenem-clavulanate added to linezolid-containing regimens in the treatment of MDR-/XDR-TB. Eur. Respir. J. 2013, 41, 1386-1392. [CrossRef] [PubMed].
30. Payen, M. C.; de Wit, S.; Martin, C.; Sergysels, R.; Muylle, I.; van Laethem, Y.; Clumeck, N. Clinical use of meropenem-clavulanate combination for extensively drug-resistant tuberculosis. Int. J. Tuberc. Lung Dis. 2012, 16, 558-560. [CrossRef] [PubMed].
31. Tiberi, S.; D'Ambrosio, L.; de Lorenzo, S.; Viggiani, P.; Centis, R.; Sotgiu, G.; Alffenaar, J. W. C.; Migliori, G. B. Ertapenem in the treatment of MDR-TB: First clinical experience. Eur. Respir. J. 2016, 47, 333-336. [CrossRef] [PubMed].
32. Van Rijn, S. P.; van Altena, R.; Akkerman, O. W.; van Soolingen, D.; van der Laan, T.; de Lange, W. C. M.; Kosterink, J. G. W.; van der Werf, T. S.; Alffenaar, J. W. C. Pharmacokinetics evaluation of ertapenem in patients with treatment of multidrug-resistant tuberculosis. Eur. Respir. J. 2016, in press.
33. Chambers, H. F.; Turner, J.; Schecter, G. F.; Kawamura, M.; Hopewell, P. C. Hopewell. Imipenem for treatment of tuberculosis in mice and humans. Antimicrob. Agents Chemother. 2005, 49, 2816-2821. [CrossRef] [PubMed].
34. Arbex, M. A.; Siqueira, H. R. D.; D'Ambrosio, L.; Migliori, G. B. The challenge of managing the extensively drug-resistant tuberculosis at a referral hospital in the state of São Paulo, Brazil: A report of three cases. J. Bras. Pneumol. 2015, 41, 554-559. [CrossRef] [PubMed].
35. Yew, W. W.; Wong, C. F.; Lee, J.; Wong, P. C.; Chan, C. H. Do_-lactam-_-lactmase inhibitor combinations have a place in the treatment of multidrug-resistant pulmonary tuberculosis? Tuber. Lung Dis. 1995, 78, 90-92. [CrossRef].
36. Hugonnet, J. E.; Blanchard, J. S. Irreversible inhibition of Mycobacterium tuberculosis_-lactamase by clavulanate. Biochemistry 2007, 46, 11198-12004. [CrossRef] [PubMed].
37. Hugonnet, J. E.; Tremblay, L. W.; Boshoff, H. I.; Barry, C. E.; Blanchard, J. S. Meropenem-clavulanate is effective against extensively drug-resistant Mycobacterium tuberculosis. Science 2009, 323, 1215-1218. [CrossRef] [PubMed].
38. Payen, M.; Martin, C.; Antoine-Moussiaux, T.; deWit, S.; Clumeck, N. Four Cases of XDR-TB Treated with Meropenem-Clavulanate. In Proceedings of the 50th Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), Boston, MA, USA, 12-15 September 2010.
39. Veziris, N.; Truffot, C.; Mainardi, J. L.; Jarlier, V. Activity of carbapenems combined with clavulanate against murine tuberculosis. Antimicrob. Agents Chemother. 2011, 55, 2597-2600. [CrossRef] [PubMed].
40. Palmero, D.; Montaner, P. G.; Cufré, M.; García, A.; Vescovo, M.; Poggi, S. First series of patients with XDR and pre-XDR TB treated with regimens that included meropenen-clavulanate in Argentina. Arch. Bronconeumol. 2015, 51, e49-e52. [CrossRef] [PubMed].
41. Tiberi, S.; Payen, M.-C.; Sotgiu, G.; D'Ambrosio, L.; Guizado, V. A.; Alffenaar, J. W.; Arbex, M. A.; Caminero, J. A.; Centis, R.; de Lorenzo, S.; et al. Effectiveness and safety of meropenem/clavulanatecontaining regimens in the treatment of multidrug and extensively drug-resistant tuberculosis. Eur. Respir. J. 2016, in press. [CrossRef].
42. Tiberi, S.; Sotgiu, G.; D'Ambrosio, L.; Centis, R.; Arbex, M. A.; Alarcon, A. E.; Alffenaar, J. W.; Caminero, J. A.; Gaga, M.; Gualano, G.; et al. Comparison of effectiveness and safety of imipenem/clavulanate added to an optimised background regimen (OBR) versus OBR controls regimens in the treatment of multidrug and extensively drug-resistant tuberculosis. Clin. Infect. Dis. 2016. [CrossRef] [PubMed].
43. Tiberi, S.; Sotgiu, G.; D'Ambrosio, L.; Centis, R.; Arbex, M. A.; Alarcon, A. E.; Alffenaar, J. W.; Caminero, J. A.; Gaga, M.; Gualano, G.; et al. Comparison of effectiveness and safety of imipenem/clavulanate-versus meropenem/clavulanate-containing regimens in the treatment of multidrug and extensively drug-resistant tuberculosis. Eur. Respir. J. 2016. in press.
44. World Health Organization. Definitions and Reporting Framework for Tuberculosis-2013 Revision; 2013 Document WHO/HTM/TB/2013. 2; World Health Organization: Geneva, Switzerland, 2013.
45. Moher, D.; Liberati, A.; Tetzlaff, J.; Altman, D. G.; Group, T. P. Preferred reporting items for systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med. 2009, 6, e1000097. [CrossRef] [PubMed].
46. Kempker, R. R.; Kipiani, M.; Mirtskhulava, V.; Tukvadze, N.; Magee, M. J.; Blumberg, H. M. Acquired drug resistance in mycobacterium tuberculosis and poor outcomes among patients with multidrug-resistant tuberculosis. Emerg. Infect. Dis. 2015, 21, 992. [CrossRef] [PubMed].
47. ClinicalTrials. Available online: https://clinicaltrials. gov (accessed on 26 February 2016).
48. Sotgiu, G.; Mauch, V.; Migliori, G. B.; Benedetti, A. Evidence-based, agreed-upon health priorities to remedy the tuberculosis patient's economic disaster. Eur. Respir. J. 2014, 43, 1563-1566. [CrossRef] [PubMed].
49. Winters, N.; Butler-Laporte, G.; Menzies, D. Efficacy and safety of World Health Organization group 5 drugs for multidrug-resistant tuberculosis treatment. Eur. Respir. J. 2015, 46, 1461-1470. [CrossRef] [PubMed].
50. Alsaad, N.; Wilffert, B.; van Altena, R.; de Lange, W. C.; van der Werf, T. S.; Kosterink, J. G.; Alffenaar, J. W. C. Potential antimicrobial agents for the treatment of multidrug-resistant tuberculosis. Eur. Respir. J. 2014, 43, 884-897. [CrossRef] [PubMed].
51. Alsaad, N.; van Altena, R.; Pranger, A. D.; van Soolingen, D.; de Lange, W. C.; van der Werf, T. S.; Kosterink, J. G.; Alffenaar, J. W. C. Evaluation of co-trimoxazole in the treatment of multidrug-resistant tuberculosis. Eur. Respir. J. 2013, 42, 504-512. [CrossRef] [PubMed].
52. Krieger, D.; Vesenbeckh, S.; Schönfeld, N.; Bettermann, G.; Bauer, T. T.; Rüssmann, H.; Mauch, H. Mefloquine as a potential drug against multidrug-resistant tuberculosis. Eur. Respir. J. 2015, 46, 1503-1505. [CrossRef] [PubMed].
53. Matteelli, A.; D'Ambrosio, L.; Centis, R.; Tadolini, M.; Migliori, G. B. Compassionate and optimum use of new tuberculosis drugs. Lancet Infect. Dis. 2015, 15, 1131-1132. [CrossRef].
54. Lönnroth, K.; Migliori, G. B.; Abubakar, I.; D'Ambrosio, L.; de Vries, G.; Diel, R.; Douglas, P.; Falzon, D.; Gaudreau, M. A.; Goletti, D.; et al. Towards tuberculosis elimination: An action framework for low-incidence countries. Eur. Respir. J. 2015, 45, 928-952. [CrossRef] [PubMed].